2021
DOI: 10.1089/thy.2021.0221
|View full text |Cite
|
Sign up to set email alerts
|

DNA Methylation Patterns in the HLA-DPB1 and PDCD1LG2 Gene Regions in Patients with Autoimmune Thyroiditis from Different Water Iodine Areas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
8
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 12 publications
1
8
0
Order By: Relevance
“…In this study, compared with the control group, the expression of PD‐L1 mRNA and PD‐L2 mRNA in the whole blood of mice in the SAT group was significantly increased; the expression of PD‐L2 mRNA was significantly increased; the PD‐1 protein in the thyroid tissue was upregulated in the SAT group; in addition, flow cytometry results showed that the surface PD‐L1 and PD‐L2 of CD3+CD4+ T cells and CD3+CD8+ T cells in the whole blood of mice in the SAT group were significantly higher than those in the control group, suggesting that PD‐1/PD‐L1/PD‐L2 overexpression may be involved in the pathogenesis of SAT, which is consistent with previous research on autoimmune diseases 22–25 . During the pathogenesis of autoimmune diseases, there is a high expression of PD‐1/PD‐L , and the expression of PD‐L2 in whole blood is increased in the SAT group, which is consistent with the results of our previous population research 11 …”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…In this study, compared with the control group, the expression of PD‐L1 mRNA and PD‐L2 mRNA in the whole blood of mice in the SAT group was significantly increased; the expression of PD‐L2 mRNA was significantly increased; the PD‐1 protein in the thyroid tissue was upregulated in the SAT group; in addition, flow cytometry results showed that the surface PD‐L1 and PD‐L2 of CD3+CD4+ T cells and CD3+CD8+ T cells in the whole blood of mice in the SAT group were significantly higher than those in the control group, suggesting that PD‐1/PD‐L1/PD‐L2 overexpression may be involved in the pathogenesis of SAT, which is consistent with previous research on autoimmune diseases 22–25 . During the pathogenesis of autoimmune diseases, there is a high expression of PD‐1/PD‐L , and the expression of PD‐L2 in whole blood is increased in the SAT group, which is consistent with the results of our previous population research 11 …”
Section: Discussionsupporting
confidence: 91%
“…However, the role of PD‐1/PD‐L in the occurrence and development of AIT is still uncertain. According to our previous 850 k chip methylation sequencing of AIT cases and healthy people in iodine deficient and iodine excess areas, 11 there were differences in the methylation levels of PDCD1LG2_1 and multiple CpG sites in the target region of the PD‐L2 gene, and further verification studies also found that the relative expression levels of PD‐L2 mRNA in AIT cases were higher than those in healthy controls, and there was a negative correlation between them, suggesting that PD‐L2 was involved in the occurrence and development of the disease.…”
Section: Introductionmentioning
confidence: 99%
“…According to the previous Illumina 850k DNA methylation chip analysis results of our research group, which was performed on ten AIT patients and ten matched controls (27) , we found the methylation differences of several apoptotic function-related genes between AIT cases and healthy controls. In combination with searching related literature, we finally chose the following five extrinsic apoptotic signalling pathway-related genes as the candidate genes: DAPK1, TNFAIP8, TNF superfamily member 8 (TNFSF8), homeobox A5 (HOXA5) and PF4.…”
Section: Selection Of Candidate Genes and Dna Methylation Analysismentioning
confidence: 81%
“…These colorectal cancer responsible genes might be candidate genes for CD. Recently, increasing evidence demonstrated that CXCL5 [379], S100A8 [380], LCN2 [381], CXCL1 [382], S100A9 [383], CXCL9 [384], CXCL11 [385], CXCL10 [386], NCF2 [387], SLC11A1 [388], GDF15 [389], IL1RN [390], STAT1 [391], CYP27B1 [392], SOCS3 [393], TLR8 [394], CD55 [395], ADGRG3 [396], CCL3 [397], FCGR2A [398], CCL2 [399], CD14 [400], IGFBP2 [401], PCSK9 [402], IDO1 [403], FOXP3 [404], CD163 [405], CCL7 [406], TLR2 [407], CCR2 [408], IL20RA [409], S100P [410], ADAMTS1 [411], TIMP1 [412], ICAM1 [413], IFNG (interferon gamma) [414], TREM2 [415], APOE (apolipoprotein E) [416], CCR1 [417], IL6 [418], CTHRC1 [419], PDCD1LG2 [420], CCL4 [421], IL11 [422], COL1A1 [423], MMP2 [424], IL1A [425], CD24 [426], POSTN (periostin) [427], GZMB (granzyme B) [428], BCL2A1 [429], CSF2 [430], TDO2 [431], CTLA4 [432], PADI4 [433], MPO (myeloperoxidase) [434], HP (haptoglobin) [435], MUC5B [436], MMP7 [437], PON3 [438], ABHD6 [439], AICDA (activation induced cytidine deaminase) [440], UGT1A6 [441], CYP2D6 [442], CYP3A5 [443], DGAT1 [444], FCRL4 [445], SLC22A4 [446], DPP4 [447], ACE (angiotensin I converting enzyme) [448], SLC5A11 [449], VIPR1 [450], FCRL3 [451], CD160 [452] and IL22RA2 […”
Section: Discussionmentioning
confidence: 99%